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Abstract
At present, 51 genes are already known to be responsible for Non-Syndromic hereditary Hearing Loss (NSHL), but the
knowledge of 121 NSHL-linked chromosomal regions brings to the hypothesis that a number of disease genes have still to
be uncovered. To help scientists to find new NSHL genes, we built a gene-scoring system, integrating Gene Ontology, NCBI
Gene and Map Viewer databases, which prioritizes the candidate genes according to their probability to cause NSHL. We
defined a set of candidates and measured their functional similarity with respect to the disease gene set, computing a score
(SSM avg) that relies on the assumption that functionally related genes might contribute to the same (disease) phenotype.
A Kolmogorov-Smirnov test, comparing the pair-wise SSM avg distribution on the disease gene set with the distribution on
the remaining human genes, provided a statistical assessment of this assumption. We found at a p-valuev2:2:10{16 that
the former pair-wise SSM avg is greater than the latter, justifying a prioritization strategy based on the functional similarity
of candidate genes respect to the disease gene set. A cross-validation test measured to what extent the SSM avg ranking for
NSHL is different from a random ordering: adding 15% of the disease genes to the candidate gene set, the ranking of the
disease genes in the first eight positions resulted statistically different from a hypergeometric distribution with a p-
value~2:04:10{5 and a powerw0:99. The twenty top-scored genes were finally examined to evaluate their possible
involvement in NSHL. We found that half of them are known to be expressed in human inner ear or cochlea and are mainly
involved in remodeling and organization of actin formation and maintenance of the cilia and the endocochlear potential.
These findings strongly indicate that our metric was able to suggest excellent NSHL candidates to be screened in patients
and controls for causative mutations.
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Introduction
Non Syndromic hereditary Hearing Loss (NSHL) is one of the
most genetically heterogeneous disorders known. Indeed it can
present an autosomal recessive, autosomal dominant, X-linked or
mitochondrial pattern of inheritance; furthermore, mutations in
the same gene may cause syndromic or non syndromic hearing
loss, and recessive forms may be caused by a combination of two
mutations in different genes from the same functional group [1].
Due to this tremendous genetic heterogeneity, the identification
of genes and gene defects that affect the process of hearing is
challenging [1]. At present 51 genes have been already identified
to be responsible, if mutated, for this phenotype (see Table 1 for
references); nevertheless not all these genes have been fully
characterized. They usually are involved in the inner ear
development or functionality, and their mutations generally cause
hearing loss interfering in the process of the elaboration of sound.
About 50% of cases of NSHL are due to mutations of GJB2, a
gene coding for a gap-junction protein called connexin 26,
involved in the cell-cell communication process. Another impor-
tant gene responsible for NSHL is GJB6, belonging to the same
family of GJB2 and adjacent to it. The identification of these two
genes highlighted the role of connexins, and therefore of the
cochlear gap-junction ion channels, in the auditory function [2,3].
However the biology of hearing is extremely complex and many
other different classes of genes are involved in NSHL. For
instance, SLC26A4, associated with autosomal recessive NSHL
[4] and Pendred syndrome, is a gene coding for pendrin, a
chloride/iodide transporter; COCH, responsible for autosomal
dominant non syndromic post-lingual with a progressive onset in
adulthood [5], encodes for cochlin, a component of the
extracellular matrix of the inner ear; POU3F4, responsible for
an X-linked non syndromic progressive and profound sensorineu-
ral hearing loss [6], encodes for a transcription factor; while WFS1
associated with autosomal recessive Wolfram syndrome and
autosomal dominant low frequency NSHL [7,8], is a gene coding
for the glycoprotein wolframin.
Moreover, several linkage studies over the years have shown
that many chromosomal regions are involved in NSHL. At present
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e12742121 loci are known to be involved in this phenotype [9], and for
many of them the genes causing NSHL have not been identified
yet. Due to their often extremely large dimensions – they can even
contain several hundreds of genes – it is not feasible to
experimentally validate all the genes contained in each locus. In
addition, some loci might contain more than one disease gene, as
in the case of DFNA3 that harbors GJB2 and GJB6.
In this scenario, a bioinformatic approach to narrow down the
list of possible candidate genes is an essential requirement in order
to experimentally validate first those genes most likely associated
with the disease.
Many strategies have been devised to address this issue, mostly
sharing the common prioritization idea of ranking the candidate
genes on the basis of their similarity with a set of training genes –
genes already associated to the phenotype – relying on the main
assumption that genes whose dysfunction contributes to a disease
phenotype tend to be functionally related (see [10] and references
within).
Quantifying the functional relatedness between two genes is not
trivial; often existing information about gene function are
exploited to infer functional relationships among genes. In this
kind of approach an excellent means is provided by Gene
Ontology (GO, The Gene Ontology Consortium, 2001) [11],
which is the golden standard ontology in the field of genes and
gene products.
Indeed one of the advantages of having genes annotated with
GO terms is the possibility to compare them not only from a
qualitative point of view (e.g. by searching for common terms with
which they are annotated), but also by defining an explicit
semantic similarity measure which reflects the closeness in
meaning between the terms with which they are annotated
[12,13]. This semantic similarity measure gives in turn a measure
of the functional similarity of the annotated gene products, as
extensively discussed in Pesquita et al [12].
Briefly, when comparing two terms in an ontology, two main
approaches are generally distinguished, the edge-based, which
counts the edges in the graph path between two terms [14–18],
and the node-based, which looks at the properties of the terms,
their ancestors and descendants [19–25]. Most of the node-based
similarity measures are functions of the information content (IC)o f
each term, and their most informative common ancestors [25]. IC
is the amount of information a term contains, meaning that a term
contains less information if it occurs very often; in this context the
similarity between two terms is quantified looking at the amount of
information they share. Very often gene products are annotated
with multiple GO terms, in this case maximum [26,27], average
[13,18,28] or sum [29] of the GO term similarities may be taken as
the gene similarity.
Table 1. NSHL disease genes.
Gene Symbol Locus Name
Chromosomal
Location References
DIAPH1 DFNA1 [5q31.3c] [43]
GJB3 DFNA2 [1p34.3f] [44]
KCNQ4 DFNA2 [1p34.2c] [45]
GJB2 DFNA3/DFNB1A [13q12.11a] [2]
GJB6 DFNA3/DFNB1B [13q12.11b] [3,46]
MYH14 DFNA4 [19q13.33c] [47]
DFNA5 DFNA5 [7p15.3a] [48]
WFS1 DFNA6/DFNA14 [4p16.1f] [7,8]
TECTA DFNA8/DFNA12/DFNB21 [11q23.3h] [49]
COCH DFNA9 [14q12e] [5]
EYA4 DFNA10 [6q23.2c] [50]
MYO7A DFNA11/DFNB2 [11q13.5c] [51]
COL11A2 DFNA13/DFNB53 [6p21.32a] [52]
POU4F3 DFNA15 [5q32d] [53]
MYH9 DFNA17 [22q12.3d] [54]
ACTG1 DFNA20/DFNA26 [17q25.3f] [55,56]
MYO6 DFNA22/DFNB37 [6q14.1a] [57]
GRHL2 DFNA28 [8q22.3a-q22.3b] [58]
TMC1 DFNA36/DFNB7/DFNB11 [9q21.13a] [59]
CRYM DFNA40 [16p12.2b] [60]
CCDC50 DFNA44 [3q28d] [61]
MYO1A DFNA48 [12q13.3a] [62]
KCNJ10 DFNA49 [1q23.2c] [63]
MIRN96 DFNA50 [7q32.2a] [64]
MYO15A DFNB3 [17p11.2g-7p11.2f] [65]
SLC26A4 DFNB4 [7q22.3c] [4]
TMIE DFNB6 [3p21.31a] [66]
TMPRSS3 DFNB8/DFNB10 [21q22.3b] [67]
OTOF DFNB9 [2p23.3b] [68]
CDH23 DFNB12 [10q22.1d-10q22.1e] [69]
STRC DFNB16 [15q15.3a] [70]
USH1C DFNB18 [11p15.1d] [37,38]
OTOA DFNB22 [16p12.2a] [71]
PCDH15 DFNB23 [10q21.1b-10q21.1c] [72]
RDX DFNB24 [11q22.3d] [73]
TRIOBP DFNB28 [22q13.1a] [74,75]
CLDN14 DFNB29 [21q22.13a] [76]
MYO3A DFNB30 [10p12.1b] [77]
WHRN(DFNB31) DFNB31 [9q32e] [78]
ESRRB DFNB35 [14q24.3c] [79,80]
ESPN DFNB36 [1p36.31a] [81]
HGF DFNB39 [7q21.11c-q21.11d] [82]
KIAA1199 DFNB48 [15q25.1b] [83]
MARVELD2 DFNB49 [5q13.2a] [84]
PJVK(DFNB59) DFNB59 [2q31.2b] [85]
SLC26A5 DFNB61 [7q22.1g] [86]
LRTOMT DFNB63 [11q13.4] [87]
LHFPL5 DFNB66/DFNB67 [6p21.31b] [40,88,89]
PRPS1 DFN2 [Xq22.3b] [90]
Gene Symbol Locus Name
Chromosomal
Location References
POU3F4 DFN3 [Xq21.1d] [6]
ATP2B2 [3p25.3b] [91,92]
GeneIDs are from NCBI Entrez Gene database; gene symbols correspond to the
official gene names as provided by HUGO Gene Nomenclature Committee
(HGNC); locus names have been inferred from literature; chromosomal locations
are derived from the file cyto_gene.md downloaded from the NCBI Entrez Gene
ftp site and references are relative to the articles where the gene association to
NSHL was identified.
doi:10.1371/journal.pone.0012742.t001
Table 1. Cont.
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between gene products by directly extending to sets of concepts
(the gene annotations) the Lin’s idea [25] of quantifying the
similarity between two concepts in an ontology. Our metric
provides a measure of the functional similarity between two genes
and its reliability is tested in this paper in the context of gene
prioritization for NSHL. Indeed the overall aim of this paper is (i)
to support researchers in search of new genes responsible for
NSHL and (ii) provide indications about the main biological
processes, molecular functions and cellular components to be
explored to study NSHL, by defining a procedure to computa-
tionally prioritize candidate genes for their association with this
phenotype. The availability of a good training gene set for NSHL
– 51 genes already associated with this phenotype (disease genes) –
allows to select new genes most likely responsible for this
phenotype estimating their similarity with the disease gene set.
Finally we define a systematic and unbiased statistical
assessment to validate the obtained results.
Results
The candidate genes prioritized for NSHL in this study were
selected as described in the Methods section. They were prioritized
against all the genes already known to be responsible for NSHL
(disease genes, see Methods section for details on their selection),
according to a score which is function of the Semantic Similarity
Measure (SSM) estimated for each candidate-disease gene pair.
All candidate genes were ranked by computing the SSMfor each
candidate-disease gene pair; the final score used for prioritizing
each candidate was obtained as the mean of the scores estimated
for that candidate against all the disease genes and was defined
Semantic Similarity Measure Average (SSM avg).
Validation of the SSM avg for NSHL gene prioritization
Before being able to assert that the ranking produced by
SSM avg is worthy of attention and therefore evaluating it from a
biological point of view, we wanted to evaluate two main aspects
concerning our prioritization methodology. We first wanted to test
whether the main hypothesis upon which this and most of the
prioritization studies are based – genes whose dysfunction
contributes to a disease phenotype tend to be functionally related
– is quantifiable in terms of semantic similarity, especially in the
particular case of NSHL, where the complexity of the hearing
process and the complexity of the genetics of the disease both play
an important role. Second aspect is whether our metric is able to
catch this functional relatedness. To test these two aspects is
equivalent to answer the following question: are the disease genes
more functionally related than two generic human genes
according to SSM? A positive answer would yield a positive
result for both aspects at the same time, implying that the more a
candidate gene obtains a high SSM score respect to the disease
gene set, the higher is its probability to cause NSHL when
mutated. To address this issue, we estimated the pair-wise SSM
distribution on the disease gene set, and compared it with the pair-
wise SSM distribution estimated on the entire human gene set. In
Figure 1 a population pyramid shows the pair-wise SSM
distribution across the disease genes and All-human-genes sets in
two back-to-back histograms. It provides the graphical evidence
that the majority of the disease gene pairs assume SSMvalues in
the range of 0.5–0.6, much greater than those assumed by the
majority of all the remaining human genes (around 0.4). This
clearly indicates that the NSHL genes are more functionally
related in terms of SSM similarity than two generic human
genes. In order to statistically support this result, we formulated
the following test: the null hypothesis is that the pair-wise SSM
distribution in the disease genes set is equal to the pair-wise SSM
distribution in the All-human-genes set, while the alternative
hypothesis is that the former is greater than the latter, i.e. the cdf
(cumulative distribution function) of the former population is
smaller than the cdf of the latter population. The test was
performed using the bootstrap version of the Kolmogorov-
Smirnov test (ks.boot), which allows ties and is included in the R
package Matching [30]. We found a p-valuev2:2:10{16, confirm-
ing the hypothesis that the disease genes are indeed more similar
according to SSMthan two generic human genes. This evidence
shows the ability of our metric in capturing the functional
relatedness of NSHL genes respect to the rest of all human genes,
justifying therefore a gene prioritization strategy for association
with NSHL based on the SSMsimilarity of the candidate genes
with respect to the disease gene set.
In order to validate the reliability of SSM avg in ranking the
candidate genes with respect to their probability to play a
causative role in NSHL manifestation, we designed a specific
cross-validation procedure that quantifies how much the ranking
obtained with our metric differs from a random ordering of the
candidate genes. Indeed, due to the specific context we are dealing
with, i.e. the gene prioritization, we could not use the classical
cross-validation procedure, we in fact added 15% of the disease
genes randomly drawn for 10000 times from the disease gene set
to the candidates, and counted each time the number of the
diseases that fell in the top four windows of 100, 75, 50 and 8
genes. Here the candidate gene set was used exclusively to produce
noise, as the positions of the candidates in the ranking were never
evaluated during the cross-validation procedure. We in fact tested
if the number of disease genes ranked in the top windows were
significantly greater than expected when a random extraction of
100, 75, 50 and 8 genes was performed from the total (candidates
plus 15% of disease genes) gene set. In Figure 2 we report the
distributions obtained from the cross-validation procedure (in blue)
applied to the four top windows. In this figure we compare these
distributions with the hypergeometric ones (in red), which mimic
the random extraction of 100, 75, 50 and 8 genes from the 8748
genes (8740 candidate genes plus 8 disease genes). In all four cases
the two distributions are clearly distinct (i.e. the overlapping
regions are small). Moreover the means of the distributions for the
cross-validation (blue triangles in the figure) result always greater
than the means of the hypergeometric distributions (red triangles
in the figure). This confirms that the ranking computed by our
gene scoring system is significantly different from a random
ordering. This is equivalent to assert that our scoring system is able
to put at the top of the ranking those genes which are functionally
more related to the NSHL genes and thus, more likely, potentially
to cause the disease when mutated. This evidence is statistically
supported as the p-value and the power of the test for each of the
four windows (see Methods section) resulted always smaller than
0.01 and greater than 0.99, respectively (Table 2).
Analysis of the top-ranked candidate genes
The candidates ranked according to SSM avg were then
examined looking at their functions and expression sites. The
twenty top-scored genes are reported in Table 3 together with a
brief description of their functions. The number of 20 was
arbitrarily chosen, mainly thinking about the intrinsic technical
limitations of experimentally testing a great number of genes for
disease association – this is actually the reason why such
prioritization studies are becoming routine.
Half of them are reported in literature to be expressed in human
inner ear or cochlea, despite the very limited availability of gene
Hearing Loss Gene Scoring
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obtaining undamaged hair-cell samples for gene expression
experiments. For the remaining genes, six are reported to be
expressed in other organisms’ inner ear or cochlea, mainly mouse
or chicken, while four have no gene expression data for these
tissues. Taken altogether, these are important indications support-
ing the goodness of the ranking we produced in respect to the
NSHL, especially if we think that the initial candidate gene list was
not a priori filtered by any criterium except that of being all
annotated genes located in the susceptibility loci.
Moreover, looking at their functions, we found that most of the
top-ranked genes play roles compatible with a possible involve-
ment in NSHL phenotype. Among the most relevant, we identified
a) processes of remodeling and organization of actin (WDR1,
CLRN1, FLII), an essential component of the hair-cell bundle; b)
formation and maintenance of cilia (ALMS1, USH1G, CC2D2A),
the sensory organelles devoted to receive the mechanical stimulus;
c) Kz cycling and pH homeostasis in cochlear fluids (ATP6V0A4,
KCNQ1, KCNE1L), essentials for the generation and mainte-
nance of the endocochlear potential; d) signal transduction
(PTPLA, PTPN11, TBL1X, TIMM8A). They are all important
molecular mechanisms underlying the hearing process, which
involve the hair cell capability to transduce the mechanical
stimulus into electrical signal, as well as the endolymph production
and maintenance.
Stronger evidences come from some of the top-ranked genes
which are already linked to different syndromic forms of deafness:
USH1G for instance is known to cause Usher syndrome type 1G
[31], associated with sensorineural hearing impairment; for this
gene a possible role in the development and maintenance of the
stereocilia bundles is reported by Weil et al. [31]: it might in fact
function as an anchoring/scaffolding protein in hair cells and
could be involved in the functional network formed by USH1C,
CDH23 and MYO7A that is required for cohesion of the growing
hair bundle, making its role in the hearing impairment process
quite easily explainable. Similarly, KCNE1L has been associated
by Piccini et al. [32] to AMME syndrome (Alport syndrome -
mental retardation - midface hypoplasia - elliptocytosis) whose
symptoms include, among others, hearing loss, and analogous
situations are reported also for TIMM8A, involved in Mohr-
Tranebjaerg syndrome [33] and Jensen syndrome [34], and
ALMS1, involved in Alstro ¨m syndrome [35]. It is noteworthy that
the association of some top-ranked genes to syndromic deafness
forms does not exclude them from being good NSHL candidates,
as clearly demonstrated by USH1C involved both in Usher
syndrome type 1C [36], and NSHL [37,38], depending on which
mutations it undergoes.
Finally, we produced a graphical bidimensional representation
of the 20 top-ranked genes together with the disease genes using
Proxscal SPSS, which performs multidimensional scaling of
Figure 1. Similarity population pyramid. Back-to-back histograms showing the asymmetry in frequencies of SSM values (in 0.1 bin interval
between 0 and 1) among gene pairs, for disease genes (on the right) and the entire human gene set (on the left).
doi:10.1371/journal.pone.0012742.g001
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in a low-dimensional space (Figure 3). The proximity of the two
gene sets was in this way highlighted; this allowed identifying
different groups of NSHL disease genes (red balls in the figure) –
namely myosins, connexins, cadherins, ion channels and so forth –
and mapping the best candidates within these groups. The
inclusion of the top-scored candidate genes did not enlarge the
area occupied by the disease genes and their membership to the
relative subgroups was mantained in the graphical representation.
Overall, on the basis of these considerations, the majority of
them seem to be excellent candidates for subsequent studies on
NSHL patients and controls.
Functional characterization of candidate and disease
genes using GO
In order to further investigate the obtained ranking and in order
to have a more general picture of the molecular functions,
biological processes and cellular components more associated to
NSHL, as suggested by both the best candidates and disease genes,
we designed and implemented two specific statistical tests that
allowed to identify the GO terms more representative of NSHL,
Figure 2. Cross-validation and hypergeometric distributions in case of (a)100, (b)75, (c)50, (d)8 window widths. In red the
hypergeometric distributions with their expectation values (red filled triangles); in blue the distributions, estimated by cross-validation, of disease
genes in the top-ranked genes with their mean values (blue filled triangles).
doi:10.1371/journal.pone.0012742.g002
Table 2. Gene scoring system cross-validation.
Window Width Mean Value P-value Power
100 5.845 5:28:10{11 1
75 5.313 8:95:10{12 1
50 4.502 2:75:10{10 0.999
8 1.151 2:04:10{5 1
Window width indicates the number of top-ranked genes considered in the
cross-validation procedure; mean value is the number of disease genes for each
window averaged on the 10000 cross-validations; p-value and power are
computed as described in the text.
doi:10.1371/journal.pone.0012742.t002
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For the disease genes, we quantified and tested the enrichment of
gene-sets defined by functional categories provided by Gene
Ontology annotations in disease gene list. In this case the SSM
score was used to define the non-disease gene class (see Methods
section). For the candidates, we analyzed all GO terms in their
annotations, and evaluated the enrichment of the gene set
annotated with each of them, by using the SSM avg score
obtained from our ranking to quantify their association with
NSHL (see Materials and Methods section). In this case the SSM
Table 3. Top-ranked candidate genes.
Gene symbol Gene description SSMavg Ear expression Gene Functions for NSHL
WDR1 WD repeat domain 1 0.55 H. sapiens (ear)
a regulation of hair
M. musculus (inner ear)
a cell actin dynamics
f
ALMS1 Alstro ¨m syndrome 1 0.53 M. musculus (inner ear)
a normal function of cilia [93]
CD151 CD151 molecule 0.52 possible human inner ear component [94] inner ear ECM assembly [94]
(Raph blood group) M. musculus (inner ear)
a
CLRN1 clarin 1 0.52 M. musculus (inner ear)
a inner ear development
f
widely expressed in human
b F actin organization
f
protein trafficking
f
ABHD5 abhydrolase domain containing 5 0.52 M. musculus (inner ear)
a TG accumulation
f
lipid homeostasis
f
USH1G Usher syndrome 1G 0.52 H. sapiens (inner ear)
b,c cohesion of hair cell bundles
f
(ankyrin and pdz domains)
ATP6V0A4 ATPase Hz transporting 0.51 H. sapiens (cochlea)
b [95] cochlear pH homeostasis [96]
lysosomal V0 subunit a4
PRCD progressive rod-cone degeneration 0.50 no data no evidence
KCNQ1 potassium voltage-gated channel 0.50 M. musculus (inner ear)
a Kz cycling
f
KQT-like subfamily member 1
NUMB numb homolog (Drosophila) 0.50 H. sapiens (ear)
a cell fate determination
M. musculus (inner ear)
a during development
f
ZAR1 zygote arrest 1 0.50 M. musculus (cochlea, stria vascularis)
g no evidence
PTPLA protein tyrosine phosphatase-like 0.50 H. sapiens (fetal cochlea)
d signal transduction
f
(proline instead of catalytic arginine)
member A
FLII flightless I homolog (Drosophila) 0.50 H. sapiens (fetal cochlea)
d actin remodeling
PTPN11 protein tyrosine phosphatase 0.49 H. sapiens (ear)
a signal transduction
f
non-receptor type 11 M. musculus (inner ear)
a
TBL1X transducin (beta)-like 1X-linked 0.49 H. sapiens (fetal cochlea)
d signal transduction
f
M. musculus (inner ear) vescicular trafficking
f
cytoskeleton assembly
f
KCNE1L KCNE1-like 0.49 M. musculus (inner ear)
a Kz cycling
f
TIMM8A translocase of inner mitochondrial 0.49 no data signal transduction
f
membrane 8 homolog A (yeast) protein transport
f
ROM1 retinal outer segment 0.49 H. sapiens (fetal cochlea)
d cell adhesion
f
membrane protein 1
CC2D2A coiled-coil and C2 0.49 no data Cazz binding
f
domain containing 2A cilia formation
f
BARHL1 BarH-like homeobox 1 0.48 M.musculus (inner ear)
e external sensory organ
fate determination [97]
Gene expression information are taken from
aNCBI Unigene [98],
bUniProtKB [99],
cHPRD database [100],
dMorton Cochlear EST database [101], NCBI GEO [102],
ethe table of gene expression in the developing ear from the Institute of Hearing Research [103],
gBgee dataBase for Gene Expression Evolution [104] and literature. Gene function information have been inferred from
fNCBI Gene [39] and literature.
doi:10.1371/journal.pone.0012742.t003
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candidate genes, to identify those GO terms significantly
associated with the best candidates, without making any a priori
decision on which candidates should be considered as the ‘‘best’’
candidates.
This survey had the purpose to examine the ranking on a larger
scale – extending the ranking examination to the whole candidate
gene set – to possibly suggest non-obvious pathways to further look
into when studying NSHL, hence it was devised as a way to look at
the results from a different point of view (i.e. moving from a view
of NSHL in terms of genes responsible of the disease to a view of
NSHL in terms of biological processes, molecular functions and
cellular components distinctive of the disease).
We considered as significantly descriptive of the best candidate
and disease genes, those GO terms with a p-valuev0:01 and we
ordered them according to their W score, function of their p-value
and specificity in the corpus of the GO annotations.
As for the candidate genes, the enriched terms, divided into
biological processes, molecular functions and cellular components
(Table 4), include expected concepts such as ‘‘auditory receptor
cell stereocilium organization’’ (GO:0060088), ‘‘large conductance
calcium-activated potassium channel activity’’ (GO:0060072),
Figure 3. Multidimensional scaling of similarity data to represent the disease and the 20 top-scored candidate genes in a
bidimensional space.
doi:10.1371/journal.pone.0012742.g003
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GO term W Score P-value Definition Ontology
GO:0060082 17.0 0.002 eye blink reflex biological process
GO:0014010 16.3 0.005 Schwann cell proliferation biological process
GO:0034465 16.3 0.002 response to carbon monoxide biological process
GO:0060231 16.2 0.010 mesenchymal to epithelial transition biological process
GO:0021771 16.1 0.001 lateral geniculate nucleus development biological process
GO:0032344 16.0 0.002 regulation of aldosterone metabolic process biological process
GO:0045759 16.0 0.001 negative regulation of action potential biological process
GO:0045794 15.9 0.002 negative regulation of cell volume biological process
GO:0021562 15.7 0.001 vestibulocochlear nerve development biological process
GO:0050975 15.6 0.005 sensory perception of touch biological process
GO:0051451 15.6 0.004 myoblast migration biological process
GO:0031630 15.5 0.005 regulation of synaptic vesicle fusion to presynaptic membrane biological process
GO:0048790 15.5 0.005 maintenance of presynaptic active zone structure biological process
GO:0046007 15.2 0.005 negative regulation of activated T cell proliferation biological process
GO:0046541 15.0 0.005 saliva secretion biological process
GO:0048676 14.9 0.005 retinal bipolar neuron differentiation biological process
GO:0045188 14.9 0.001 regulation of circadian sleep/wake cycle, non-REM sleep biological process
GO:0050916 14.8 0.010 sensory perception of sweet taste biological process
GO:0035022 14.8 0.009 positive regulation of Rac protein signal transduction biological process
GO:0042524 14.9 0.005 negative regulation of tyrosine phosphorylation of Stat5 protein biological process
GO:0060083 14.7 0.002 smooth muscle contraction involved in micturition biological process
GO:0042320 14.7 0.001 regulation of circadian sleep/wake cycle, REM sleep biological process
GO:0051496 14.6 0.005 positive regulation of stress fiber formation biological process
GO:0030007 14.5 0.002 cellular potassium ion homeostasis biological process
GO:0001661 14.5 0.001 conditioned taste aversion biological process
GO:0051602 14.4 0.005 response to electrical stimulus biological process
GO:0032287 14.4 0.004 myelin maintenance in the peripheral nervous system biological process
GO:0050957 14.2 0.001 equilibrioception biological process
GO:0045475 14.1 0.002 locomotor rhythm biological process
GO:0001895 14.1 0.005 retina homeostasis biological process
GO:0060087 14.0 0.003 relaxation of vascular smooth muscle biological process
GO:0048484 14.0 0.007 enteric nervous system development biological process
GO:0022408 14.0 0.005 negative regulation of cell-cell adhesion biological process
GO:0060088 13.9 0.004 auditory receptor cell stereocilium organization biological process
GO:0021952 13.8 0.005 central nervous system projection neuron axonogenesis biological process
GO:0033081 13.8 0.004 regulation of T cell differentiation in the thymus biological process
GO:0051963 13.0 0.001 regulation of synaptogenesis biological process
GO:0042220 12.9 0.001 response to cocaine biological process
GO:0002262 12.9 0.004 myeloid cell homeostasis biological process
GO:0007019 12.7 0.005 microtubule depolymerization biological process
GO:0060113 12.5 0.001 inner ear receptor cell differentiation biological process
GO:0046620 12.4 0.004 regulation of organ growth biological process
GO:0007605 11.7 0.004 sensory perception of sound biological process
GO:0045039 11.5 0.005 protein import into mitochondrial inner membrane biological process
GO:0031667 9.9 0.004 response to nutrient levels biological process
GO:0019725 7.2 0.004 cellular homeostasis biological process
GO:0017071 15.9 0.005 intracellular cyclic nucleotide activated cation channel complex cellular component
GO:0032588 15.7 0.005 trans-Golgi network membrane cellular component
GO:0032839 14.1 0.004 dendrite cytoplasm cellular component
GO:0032154 13.9 0.005 cleavage furrow cellular component
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cell stereocilium organization’’ (GO:0060088), consistent with
hearing physiology, as well as less obvious functions or processes
such as ‘‘regulation of circadian sleep/wake cycle, REM and
non-REM sleep’’ (GO:0042320, GO:0045188), ‘‘response to
cocaine’’ (GO:0042220), or ‘‘mu-type opioid receptor binding’’
(GO:0031852), that need further (experimental) investigations. This
on the one hand supports again the goodness of the ranking,
confirming that the top-scored genes are actually promising
candidates for association with NSHL, on the other hand fulfils
our initial requirement to suggest new prospective insights in NSHL.
As for the disease genes, as expected, the enriched terms are all
consistent with the hearing physiology (Table 5). To give some
examples, among the most relevant enriched biological processes
we found ‘‘actin filament-based movement’’ (GO:0030048), ‘‘inner
ear morphogenesis’’ (GO:0042472), ‘‘regulation of cell shape’’
(GO:0008360) and a group involving sensory perception
(GO:0007605, GO:0007601, GO:0050957). Likewise, among the
enriched cellular components, are ‘‘stereocilium’’ (GO:0032420),
‘‘myosin complex’’ (GO:0016459), ‘‘cell junction’’ (GO:0030054),
and among the molecular functions, ‘‘actin binding’’ (GO:
0003779), ‘‘actin filament binding’’ (GO:0051015), and so
forth.
Interestingly, among all the enriched terms – for both candidate
and disease genes – there is a very small amount of overlapping.
Only two biological processes are in fact shared between the two
gene lists, ‘‘sensory perception of sound’’ (GO:0007605) and
‘‘equilibrioception’’ (GO:0050957), which are neverthless ex-
tremely specific terms – a very small number of gene products
are annotated with these terms – both deeply linked to the inner
ear function. Looking at the GO graph, however, many of the
non-shared terms are interconnected with each other on a larger
scale, sharing a common parent at different levels of specificity.
This is due to the structure of our algorithm that favours the
closeness in the graph of the terms in estimating the similarity
between genes. It is noteworthy that with this approach we can
think of NSHL from a different perspective, exploring portions of
the graph that otherwise would have never been explored.
In Figure 4 we reported an elucidative example of this issue: by
mapping some enriched disease and candidate biological processes
to the GO graph, we observed that the addition of ‘‘inner ear
receptor cell differentiation’’ (GO:0060113) to the list of NSHL
possible biological processes clearly enlarges the NSHL subgraph
covering a new branch of the ‘‘inner ear development’’
(GO:0048839) different from the ‘‘inner ear morphogenesis’’
(GO:0042472), while the addition of ‘‘auditory receptor cell
stereocilium organization’’ (GO:0060088) narrows and specializes
the concept ‘‘inner ear morphogenesis’’ to one of its components.
These findings, as a whole, on the one hand support again the
goodness of the ranking, on the other hand they suggest that also
some pathways apparently unrelated with NSHL, might deserve
future attention by NSHL researchers.
Discussion
In the perspective of discovering new genes potentially involved
in NSHL, we built a gene scoring system integrating Gene
Ontology (GO), NCBI Gene and Map Viewer databases, which
scores the candidate genes for NSHL by comparing them with the
51 NSHL disease genes already known, relying on the assumption
that functionally related genes might contribute to the same
(disease) phenotype.
We defined a set of candidate genes for NSHL as all the genes
contained in the susceptibility loci known so far, and we prioritized
them for the association with the disease, without making any a
priori selection except that of being annotated with at least one GO
term.
We first of all tested whether our metric, SSM avg, was able to
capture the above assumption, verifying that the disease genes are
indeed more similar, according to the metric, than two generic
human genes. We also demonstrated that our metric is able to pool
the disease genes respect to the other human genes, implying that
the former are indeed more closely functionally related than the
latter: these results therefore justify a prioritization strategy based on
the similarity of the candidate genes respect to the disease gene set.
Afterwards, we wanted to investigate to what extent our metric
is reliable in ranking candidate genes for their potential role in
NSHL manifestation. To this purpose we designed a cross-
validation procedure and we obtained excellent results also
considering the more disadvantageous condition of ranking eight
disease genes in the first 8 positions of a list of more than 8700
genes.
Given these preliminary validations, we are extremely confident
that the ranking we produced with respect to NSHL is worthy of
attention for future NSHL research plan. Indeed, the top-scored
candidate genes play all roles compatible with a possible
involvement in NSHL phenotype, representing therefore excellent
candidates for subsequent studies on NSHL patients and controls.
GO term W Score P-value Definition Ontology
GO:0016011 13.1 0.009 dystroglycan complex cellular component
GO:0042719 11.6 0.005 mitochondrial intermembrane space protein transporter complex cellular component
GO:0030660 10.3 0.005 Golgi-associated vesicle membrane cellular component
GO:0031852 17.0 0.005 mu-type opioid receptor binding molecular function
GO:0043533 16.3 0.008 inositol 1.3.4.5 tetrakisphosphate binding molecular function
GO:0060072 15.7 0.002 large conductance calcium-activated potassium channel activity molecular function
GO:0015266 14.4 0.004 protein channel activity molecular function
GO:0030346 14.2 0.004 protein phosphatase 2B binding molecular function
GO:0000822 13.8 0.008 inositol hexakisphosphate binding molecular function
Candidate gene enriched (p-valuev0:01) GO terms, sorted according to their W score in each ontology. W scores take into account the specificity of the terms as
described in the text.
doi:10.1371/journal.pone.0012742.t004
Table 4. Cont.
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also be taken into account when looking at these data, both
concerning the usage of Gene Ontology annotations to build the
gene profiles on which the semantic similarity is measured. One is
linked to the current knowledge about the human genome and its
content in terms of genes. Indeed, the only prerequisite for a gene to
be prioritized by our gene scoring system for a given disease is that
of being annotated with at least one GO term, but, as clearly
Table 5. Enriched biological processes, cellular components and molecular functions for disease genes.
GO term W Score P-value Definition Ontology
GO:0007605 150.4 3:10{61 sensory perception of sound biological process
GO:0007601 22.7 1:10{6 visual perception biological process
GO:0050957 22.7 0.0001 equilibrioception biological process
GO:0030048 21.2 0.0001 actin filament-based movement biological process
GO:0045494 19.5 0.001 photoreceptor cell maintenance biological process
GO:0050896 18.1 1:10{6 response to stimulus biological process
GO:0042472 17.8 0.001 inner ear morphogenesis biological process
GO:0008360 14.2 0.001 regulation of cell shape biological process
GO:0007155 14.0 0.001 cell adhesion biological process
GO:0006355 12.0 0.0005 regulation of cellular transcription, DNA-dependent biological process
GO:0006350 10.2 0.001 cellular transcription biological process
GO:0006810 7.8 0.009 transport biological process
GO:0005886 45.5 2:10{18 plasma membrane cellular component
GO:0016021 39.6 2:10{16 integral to membrane cellular component
GO:0005737 36.5 3:10{15 cytoplasm cellular component
GO:0032420 24.7 1:10{5 stereocilium cellular component
GO:0016459 23.0 1:10{6 myosin complex cellular component
GO:0005856 22.9 1:10{7 cytoskeleton cellular component
GO:0030054 22.2 1:10{6 cell junction cellular component
GO:0031941 21.9 0.0001 filamentous actin cellular component
GO:0005634 20.1 3:10{7 nucleus cellular component
GO:0016324 19.8 0.0001 apical plasma membrane cellular component
GO:0001726 18.4 0.001 ruffle cellular component
GO:0005922 18.1 0.001 connexon complex cellular component
GO:0005829 16.9 6:10{5 cytosol cellular component
GO:0005783 16.1 0.0001 endoplasmic reticulum cellular component
GO:0045202 15.2 0.001 synapse cellular component
GO:0016020 15.8 3:10{6 membrane cellular component
GO:0042995 15.1 0.0001 cell projection cellular component
GO:0005789 14.4 0.001 endoplasmic reticulum membrane cellular component
GO:0003779 29.4 8:10{10 actin binding molecular function
GO:0005516 28.5 7:10{9 calmodulin binding molecular function
GO:0051015 20.1 0.0001 actin filament binding molecular function
GO:0043531 19.8 0.001 ADP binding molecular function
GO:0003774 18.6 1:10{5 motor activity molecular function
GO:0005515 16.6 5:10{6 protein binding molecular function
GO:0004749 16.2 0.001 ribose phosphate diphosphokinase activity molecular function
GO:0042803 14.2 0.004 protein dimerization activity molecular function
GO:0005524 12.7 0.0001 ATP binding molecular function
GO:0043565 12.5 0.001 sequence-specific DNA binding molecular function
GO:0000166 11.9 0.0001 nucleotide binding molecular function
GO:0003700 11.6 0.001 transcription factor activity molecular function
Disease gene enriched (p-valuev0:01) GO terms, sorted according to their W score in each ontology. W scores take into account the specificity of the terms as described
in the text.
doi:10.1371/journal.pone.0012742.t005
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PLoS ONE | www.plosone.org 11 September 2010 | Volume 5 | Issue 9 | e12742evidencedin this study,we arestillfar from the complete annotation
of the entire human genome, as we were forced to exclude almost
half of the possible candidates since they completely lacked GO
annotations. This limitation obviously biases the results towards the
best studied genes; however it will be progressively overcome in the
future, due to the daily updates in this field. The other limitation
regards the nature of the associations between GO terms and gene
products. All the associations in Gene Ontology fall in five general
categories indicating the evidences that support the annotation of a
gene to a specificterm. Four of these categories comprise exclusively
manually-curated associations supported by experimental, compu-
tational analysis, author statements or curatorial statements.
Unfortunately the great majority of GO associations does not fall
in any of these manually-curated categories, being inferred from
electronic annotation (IEA), which may open a debate on how
reliable and precise they are. At present, given the high percentage
of IEA associations in GO, it is not conceivable to discard them and
consider only those manually-curated. Other solutions must
therefore be devised to address this issue. Future developments of
our gene scoring system could for instance take into account this
problem by down-weighting the IEA associations respect to those
manually-curated. However the quantification of the difference in
weight between the manual and electronic associations is not trivial
and requires an accurate study of the algorithms behind the
electronic associations. We reserve in future to enhance our
algorithm in this direction.
Final and essential step to confirm the results presented in this
study is however the experimental validation. To this end two
main aspects should be taken into account: (i) the accurate study
and selection among the top-ranked genes of the most intringuing
candidates for NSHL; we think for instance that the first one
(WDR1) represents a good starting point, due to both what is
known about its functions and structure – it is indeed involved in
the organization of the actin, fundamental for the auditory
process, and small enough to be quite easily sequenced in a large
number of subjects; (ii) an equally accurate selection of the
appropriate NSHL patients and controls to be screened for
causative mutations; it is advisable for instance to screen these
genes on a cohort of patients already excluded to carry mutations
in GJB2, due to the high incidence of NSHL cases caused by
mutations in this gene, and on a control set appropriately matched
for their geographic origin, in order to take into account the
geographic distribution of the human DNA sequence variation.
Methods
A total of 15727 genes (candidate genes) were prioritized for
NSHL in this study. We chose as candidate genes all the genes
contained in the NSHL susceptibility loci known so far (Tables S1,
S2, S3 respectively for NSHL autosomal dominant, autosomal
recessive and X-linked, Y-linked and modifier loci), so that all
evidences coming from previous linkage analysis studies were
taken into account.
We drew the complete disease gene list starting from the
Hereditary Hearing Loss Homepage [9] and a team of experts
(geneticists and molecular biologists) further analysed the literature
to find additional advances in the field by performing multiple
queries on PubMed. To the best of our knowledge, 51 genes
belong to this category, as reported in Table 1.
For each disease and candidate gene, we extracted all their GO
annotations using the file gene2go downloaded on 29th May 2009
from NCBI Entrez Gene ftp site [39]. One out of fifty-one disease
genes – MIRN96 – had no GO annotations, therefore it was not
included in this study, consequently narrowing the disease gene list
to fifty genes. Likewise, 6987 out of 15727 candidate genes had no
GO annotations, therefore the candidate gene list was conse-
quently narrowed to 8740 genes.
Semantic similarity between two genes
As a node-based approach, our metric computes the similarity
between two genes by comparing the GO terms describing them,
their ancestors, and their descendants in the GO network. It is
based on the Information Content (IC), which gives a measure of how
specific and informative a term is. The IC of a term c is quantified
as the negative log likelihood
IC(c)~{log(p(c)) ð1Þ
where p(c) is the probability of occurrence of c in a specific corpus,
which is normally estimated by the frequency of annotation of the
term and its children in the GO structure [24,40].
The concept of IC was used by Lin to quantify the semantic
similarity between two terms in a tree-structured ontology,
measuring the information they share normalized respect to the
information contained in their total descriptions. According to
Lin’s metric [25] the similarity between two terms c1 and c2 is
defined as:
SIM Lin~
2IC(c0(c1, c2))
IC(c1)zIC(c2)
ð2Þ
where c0(c1, c2) is the most informative common ancestor of the
terms c1 and c2, i.e. the common ancestor with the smallest p(c).
However, two aspects of this metric limit its application:
N it applies only to trees, where a unique most informative
common ancestor between two any given concepts exists;
N it measures the distance between single terms rather than set of
terms.
For the first drawback, it is well known that in the case of a
direct acyclic graph (DAG), such as GO, two terms can share
parents by multiple paths, as multiple parents for each concept are
allowed. Therefore, we chose, as c0(c1, c2), the minimum
subsumer between c1 and c2 along all their independent paths
to the graph root [13].
To address the second issue, we defined our Semantic Similarity
Measure (SSM) by directly extending Lin’s idea to quantify the
similarity between two concepts to the comparison between two
gene products, i.e. two sets of concepts, therefore measuring the IC
of the common description of the two gene products, normalized
respect to the IC of their global description.
Let be
A~fGO1A, GO2A, ..., GOnAg
Figure 4. GO subgraph of some disease and candidate gene enriched GO terms. Red circles indicate terms enriched for the disease genes,
green circles indicate terms enriched for the candidate genes. Dark blue arrows indicate is a relations, light blue arrows indicate part of relations
between the terms.
doi:10.1371/journal.pone.0012742.g004
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two gene products, annotated respectively with n and m GO
terms, that are to be compared. The idea is that each term in A is
an independent view of the gene A and has to be compared with
its counterpart in the B gene annotation, namely the term in B
with maximum IC for the common description respect to it. In
formulas, for the term GOiA, its counterpart GOiA,max in B is
defined as:
GOiA,max~arg max
GO[B
IC(c0(GOiA, GO)):
The IC for each GO term c is estimated using its probability of
occurrence p(c) in the corpus of all gene annotations provided by
ENGINE database [41,42]: in details, the probability p(c) is
calculated for every term by counting the number of gene products
associated with the term or any of its children, divided by the
number of total associations between the GO terms and gene
products.
Considering as independent the single views of a gene offered by
each of its terms, the semantic similarity of A respect to B is
estimated by the sum of the shared common description ICs
between each term in A and its counterpart in B normalized with
the IC of their global description:
SSM(A, B)~
2: IC(GO1A,max)zIC(GO2A,max)z...zIC(GOnA,max)
IC(GO1A)zIC(GO1A,max)zIC(GO2A)zIC(GO2A,max)z...zIC(GOnA)zIC(GOnA,max)
:
The similarity of the gene B respect to A (SSM(B, A))i s
obtained by inverting the roles of A and B in the above formula.
Finally, we defined our Semantic Similarity Measure between A
and B, SSM A,B, as the mean between the similarity of A respect
to B and the similarity of B respect to A:
SSM A,B~
SSM(A, B)zSSM(B, A)
2
: ð3Þ
SSM A,B generates normalized similarity values between 0 and 1:
it’s equal to 0 for genes annotated with terms that share only the
root and equal to 1 for genes annotated with the same terms.
Validation of the SSM avg for NSHL gene prioritization
A cross-validation procedure was used to check the reliability of
the ranking of candidate genes for their involvement in NSHL. A
random set of 8 disease genes was added to the set of candidate
genes for 10000 times. Each time the SSM avg values for this
enlarged set of candidates were computed against the remaining
disease genes and the number of disease genes Nd in the first
d~f100, 75, 50, 8g top-ranked positions was counted. The
corresponding wd distributions of these countings were then
compared with the probabilities of counting 0, 1, ...,8disease
genes when a random drawn of 100, 75, 50, 8 genes, respectively,
was performed from a set of 8748 genes (8740 candidate genes
plus 8 disease genes): in the case of random drawns, the countings
are described by a hypergeometric distribution with 0, 1, ...,8
successes for d draws without replacement.
More in details, we computed the p-value and the power of a
statistical test on the hypothesis of equal distributions H0 against
the hypothesis H1 of a greater number of disease genes in the first
positions for the SSM avg ranked ordering respect to the random
ordering. The p-value measures the probability to obtain, by
random extraction, a number of disease genes N’d greater than the
mean value Ndm of the number of disease genes found in the d top-
ranked positions on the 10000 cross-validations:
p-value~P(N’d§Ndm) ð4Þ
The p-value is our estimate of the probability of rejecting H0 when
H0 is true: whenever the p-value was less than the significance level
a~0:01, we maintained that the number of disease genes found in
the top-ranked positions was statistically significantly greater than
that found in random orderings.
The knowledge of the empirical distribution of Nd estimated
through the cross-validation procedure, allowed us to estimate the
power p of the test with level a: indicating with N’da the a-quantile
of the hypergeometric distribution, p is computed as follows:
p~
1
10000
X 10000
i~1
IfNdi§N’dag, ð5Þ
where Ndi is the number of disease genes found in the first d
positions for the ith randomization. The larger is the percentage of
Ndi values obtained in cross-validation that are greater than N’da,
the more effective is the gene prioritization system.
Functional characterization of candidate and disease
genes for NSHL
Candidate genes. The statistical test used to identify the
most representative GO terms associated with the candidate genes
was designed as follows: the null hypothesis is that candidate genes
annotated with a particular GO category have an average
SSM avg score equal to the average score expected for a
random list of candidate genes with the same size, whereas the
alternative hypothesis is that the GO category list has a higher
average score and, therefore, is supposed to be more associated
with the disease than a random candidate gene list. After selecting
all the GO terms associated with all the candidate genes, we
computed a p-value which scores each GO term according to the
following strategy: the higher is the number of its associated
candidates which obtained in our ranking a high SSM avg value,
the more the GO term is considered enriched in the candidate
gene list. This implies that, choosing a significance threshold of
0.01, the GO terms with p-valuev0:01 can be considered
significantly descriptive of the best candidate genes and
consequently significantly associated with the disease. This
provides directions for the NSHL researchers about the
functions to be more deeply investigated in future laboratory
experiments.
The p-value for the i-th GO term is computed as follows:
p-value(GOi)~1{Fs(m) ð6Þ
where m is the average of the SSM avg scores resulting for
candidate genes annotated with GOi, s is the number of candidate
genes annotated with the GOi category, Fs is the empirical
cumulative distribution for the SSM avg scores, averaged on lists
of candidate genes of size s. Fs was computed by drawing 10000
random lists of candidate genes of size s and averaging the
respective gene scores.
Disease genes. After selecting all the GO terms used to
annotate the disease genes, we computed for each GO term a
Fisher’s exact test p-value which scores the GO category (GO Term
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expected belong to the category. The contingency table (Table 6)
is built by counting the disease and non-disease genes associated
and not associated with the GO category.
The definition of the non-disease class is not trivial, as it is not
possible to know in advance which candidate genes will be
discovered as responsible for NSHL in the future – i.e. it is not
possible to discriminate disease and non-disease genes among the
candidates. To address this issue we decided to use the distribution
of SSM scores in the class of candidate genes to define the non-
disease class. We considered as non-disease genes the candidate
genes with a score less than the 95th percentile of the distribution
of candidate gene scores.
The GO terms with a Fisher’s test p-value smaller than 0.01 are
considered significantly over-represented in the list of the disease
genes. These provide indications about the main functions and
biological processes involved in the hearing mechanisms, taking
into account the SSM avg scores computed for our candidate gene
list against the NSHL genes at present known.
W score. For both candidate and disease gene lists their over-
represented GO terms are weighted taking into account their
specificity in the corpus of the GO annotations as follows:
W~{log(p-value)zIC
where IC is estimated using the probability of occurrence of the
GO terms in the corpus of all gene annotations provided by
ENGINE database [41,42].
Supporting Information
Table S1 NSHL autosomal dominant loci. Locus names and
chromosomal locations have been inferred from literature.
References are relative to the articles where the locus association
to NSHL was identified.
Found at: doi:10.1371/journal.pone.0012742.s001 (0.05 MB
PDF)
Table S2 NSHL autosomal recessive loci. Locus names and
chromosomal locations have been inferred from literature.
References are relative to the articles where the locus association
to NSHL was identified.
Found at: doi:10.1371/journal.pone.0012742.s002 (0.05 MB
PDF)
Table S3 NSHL X-linked, Y-linked and modifier loci. Locus
names and chromosomal locations have been inferred from
literature. References are relative to the articles where the locus
association to NSHL was identified.
Found at: doi:10.1371/journal.pone.0012742.s003 (0.02 MB
PDF)
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